Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
Movement Disorders Clinical Practice2023Vol. 10(6), pp. 943–955
Citations Over TimeTop 13% of 2023 papers
Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell‐Garcia, Cornelis Blauwendraat, Ethan Brown, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, Doug Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Tanya Simuni, Andrew Siderowf, Andrew Singleton, John Seibyl, Caroline M. Tanner, the Parkinson's Progression Markers Initiative
Abstract
Parkinson's Progression Markers Initiative is registered with ClinicalTrials.gov (NCT01141023).
Related Papers
- → Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?(2003)93 cited
- → Early neuropsychological detection and the characteristics of Parkinson's disease associated with mild dementia(2008)27 cited
- → Dopamine agonists in the treatment of Parkinson's Disease(1995)12 cited
- Effects of levodopa and dopamine on the number and function of dopamine transporter(2003)
- Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo patients with Parkinson's disease(2014)